Protein Sciences Corporation
1000 Research Parkway, Meriden CT 06450 USA
Executive Offices, Pilot Plant cGMP Manufacturing, Quality Assurance, Research Antigens, Cell Culture
875 Research Parkway, Meriden CT 06450 USA
Business Development, Finance, Quality Control, Regulatory Affairs, Pilot Plant cGMP Manufacturing, Product Realization Laboratory, Clinical Affairs
401 North Middletown Road, Pearl River NY 10965 USA
Large scale cGMP Manufacturing
- Mertiva AB (Sweden)
- Johnson & Johnson
- Pacific Rim Ventures (Japan)
- Diamyd Therapeutics (Sweden)
- UMN Pharma (Japan)
- Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA): HHS0100200900106C
Advanced Development of Recombinant Influenza Virus Vaccines
Investor Relations Contact:
Executive Chairman and Global Head of Business Development
Shareholder Relations Contact:
Director, Corporate Communications and Shareholder Relations
We are a privately held company founded in 1983. We generate revenue through technology licenses, GeneXpress product development and
manufacturing services and our research antigens business, and have been self financing since 2006.
Our revenues have grown rapidly to over $31 million in 2012 and we have been increasingly profitable and cash flow positive since 2009.
Our lead product, Flublok influenza vaccine, was approved by the U.S. FDA in January 2013 for adults 18-49 years old.
We anticipate FDA approval of Flublok for use in people 50 years of age and older in early 2014.
Request More Information